⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ARQT News
Arcutis Biotherapeutics, Inc. Common Stock
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
ARQT
Form 8-K
sec.gov
ARQT
Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update
globenewswire.com
ARQT
Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months
globenewswire.com
ARQT
Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines
globenewswire.com
ARQT
THE SKIN OF COLOR SOCIETY (SOCS) SUCCESSFULLY PRESENTS LANDMARK SYMPOSIUM CHAMPIONING EVIDENCE-BASED DERMATOLOGY AND COLLABORATION
prnewswire.com
ABBV
JNJ
ARQT
BMY
LLY
INCY
SNY
REGN
PFE
UCB
BIIB
ORGN
TAK
ELMD
Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
globenewswire.com
ARQT
The Credibility Filter Wall Street Uses to Sort Biotech Winners
globenewswire.com
ARQT
ANVS
STOK
NTLA
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
globenewswire.com
ARQT
PVLA
INCY
Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference
globenewswire.com
ARQT